MHRA-101549-PIP01-24

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Afimkibart
Invented Name
Not yet available
PIP Number MHRA-101549-PIP01-24
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection/infusion
Therapeutic area
Therapeutic area:
  • Gastroenterology-Hepatology
Conditions / Indications
Conditions / Indications:
  • Treatment of ulcerative colitis
Route(s) of administration
Route(s) of administration:
  • INTRAVENOUS USE SUBCUTANEOUS USE
PIP applicant
  • Roche Products Limited
  • Country United Kingdom
  • Tel 07771398016
  • Email uk.dra@roche.com
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Afimkibart.pdf
Published Date 11/09/2025